Community Practice Connections™: Guidebook for Community Oncology NSCLC Treating Teams to Administer EGFR Exon 20-Targeted Regimens
Community Practice Connections™: Guidebook for Community Oncology NSCLC Treating Teams to Administer EGFR Exon 20-Targeted Regimens is organized by Physicians' Education Resource, LLC (PER).
Release Date: March 29, 2023
Expiration Date: March 29, 2024
Description:
EGFR exon 20 insertion mutations are the third most common oncogenic molecular aberration associated with EGFR in patients with non-small cell lung cancer (NCSLC). These mutations are generally insensitive to classical EGFR kinase inhibitors. New advances in therapy have led to approval of 2 novel treatment options in this setting.
This Community Practice Connection™ program provides a review of some of the key highlights from the multimeeting educational activity, “Oncology Best Practice: Guidebook for Community Oncology NSCLC Treating Teams to Administer EGFR Exon 20–Targeted Regimens.” This multimedia activity is ideal for community-based clinicians, focusing on key takeaways and practical advice for managing patients with EGFR-mutated NSCLC and using written summaries supplemented by interviews with world experts in the treatment of these tumors. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Determine optimal molecular testing strategies for patients with NSCLC and EGFR exon 20 insertions along the disease continuum
• Explain clinical trial data from studies that have evaluated EGFR exon 20-targeted agents in for patients with advanced NSCLC and EGFR exon 20 insertions
• Apply personalized treatment approaches for patients with EGFR exon 20 insertions across multiple lines of therapy
• Delineate multidisciplinary strategies to identify and manage treatment-related adverse events associated with EGFR exon 20-targeted regimens.